Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infudopa PK vs Duodopa in Advanced Parkinson's
NCT03419806Phase 1Completed
- Sponsor
- Region Västra Götaland
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Infudopa in Parkinson's disease (PD) (3 arms), sponsored by Region Västra Götaland. Primary endpoints: Steady state plasma concentration - levodopa at 24 hours, Area under plasma concentration versus time curve - levodopa at 24 hours and 1 more. Started Feb 2018; status: completed.
02
Drugs
Infudopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03419806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419806.